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Objectives: G protein-coupled receptor 30 (GPR30) is a 7-transmembrane estrogen receptor that functions
alongside traditional estrogen receptors to regulate the cellular responses to estrogen. Recent studies suggest that
GPR30 expression is associated with a poor prognosis, and that this is due to the GPR30-mediated transactivation of
the EGFR in breast cancer. However, the biological contribution of GPR30 in ovarian cancer remains unclear. The
purpose of this study was to elucidate the relationships between GPR30 expression and the clinicopathological
findings, and to determine how the signaling cascade influences the prognosis of ovarian cancer.
Methods: The expression levels of GPR30, EGFR, ERα, and ERβ were analyzed using an immunohistochemical
analysis, and their correlations with the clinicopathological features were examined in 10 patients with borderline
malignant tumors and 152 patients with epithelial ovarian cancer. We also examined whether GPR30 signaling
activates the EGFR-Akt pathway in an ovarian cancer cell line (Caov-3) by a Western blotting analysis.
Results: The GPR30 expression in ovarian carcinomas was significantly higher than that in borderline malignancies
(p=0.0016), and was not associated with the expression of the EGFR, ERα, or ERβ. The expression of GPR30 in clear
cell carcinomas was significantly lower than that in other subtypes of cancer (P < 0.001). The expression of both
GPR30 and EGFR was significantly associated with a poor prognosis in terms of the progression-free survival rate.
The phosphorylation of the EGFR and Akt could be significantly enhanced by G1 (p < 0.05) and inhibited by a Src
family kinase inhibitor.
Conclusion: The expression of both GPR30 and EGFR is associated with a poor outcome in ovarian cancer, and
GPR30 increases the phosphorylation of Akt via the EGFR in ovarian cancer cells. The regulation of GPR30 might be
a potentially useful new therapeutic target in ovarian cancer.
Keywords: G protein-coupled receptor 30, GPR30, 7-transmembrane estrogen receptor, EGFR, Akt, ERα; Clear cell
carcinomas, Prognostic factorIntroduction
Ovarian cancer is the most common cause of
gynecological cancer-related death. Approximately 70%
of all patients with ovarian cancer are diagnosed at an
advanced stage, and 60% to 80% of patients die of the
disease [1]. The main reasons for the poor prognosis are
the high recurrence rate and resistance to second-line
chemotherapeutics. Therefore, the development of new* Correspondence: y-terai@poh.osaka-med.ac.jp
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reproduction in any medium, provided the ortherapies is critical for the treatment of ovarian cancer
patients.
Estrogens are major regulators of growth and differen-
tiation in the normal ovaries, and also play an important
role in the progression of ovarian cancer. Likewise, a
marked proliferative response to estrogens was shown in
ovarian surface epithelial cells, which are the site of 90%
of malignancies [2], and an increased risk of ovarian
tumors was observed in postmenopausal patients receiv-
ing estrogen replacement therapy [3-5]. The biological
effects of estrogens are classically mediated by thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hormone-inducible transcription factors that bind to the
estrogen-responsive elements (EREs) located within the
promoter regions of target genes [6]. Moreover, it has
been suggested that the nongenomic actions of estro-
gens, as well as the genomic effects, are susceptible to
interference from environment estrogens [7]. However,
the precise identity and function of many steroid mem-
brane receptors are still controversial in terms of their
specific molecular interactions with endogenous and en-
vironmental estrogens. Many studies have demonstrated
that ERβ is highly represented in normal ovarian epithe-
lial cells and benign tumors, whereas ERα is the main
form expressed in ovarian cancer [8-11]. The ERβ
mRNA expression is inversely correlated with tumor
progression, while the ERα mRNA expression is posi-
tively correlated with the progression [10,12]. The ER α/
β mRNA ratio is markedly increased in ovarian cancer
[9]. In contrast with breast cancer, the prognostic value
of the ERα or ERβ status, as well as the prediction of the
responsiveness to anti-estrogen treatment, have not been
clearly established for ovarian cancer [3-15].
The G protein-coupled receptor 30 (GPR30), which
mediates the nongenomic signaling of 17-beta-estradiol
(E2), is widely expressed in cancer cell lines and primary
malignant tumors of the breast, endometrium, prostate
and lungs [16,17], and is strongly associated with the
proliferation, invasion, metastasis, and drug resistance of
various cancer cell lines [18-24]. GPR30 protein expres-
sion correlates with the clinical and pathological biomar-
kers of a poor outcome in breast cancer and endometrial
cancer [25,26]. Recent studies have shown that GPR30
exerts its effects through the activation of the epidermal
growth factor receptor (EGFR) transduction pathway in
endometrial cancer, breast cancer, and thyroid cancer
cells [19,20,27-29]. Moreover, Filardo et al. found that
estrogen rapidly activated extracellular signal-related
kinase (ERK) 1/2 via EGFR transactivation in breast can-
cer cell lines, regardless of their ER status [20]. Signaling
via the EGFR leads to multiple downstream events; for
example, activation of phospholipase C (PLC), the
phosphatidylinositol-3 kinase (PI3K)/Akt pathway and
MAPK. The EGFR is reported to be present in 33-75%
[30] of ovarian cancers and has been implicated in both
the growth and progression of this disease [31]. Akt acti-
vation is closely related to cancer cell growth, because it
affects cancer cell survival, proliferation (leading to an
increased cell number) and growth (increasing the cell
size) [32-34].
Only one previous study has shown that high levels of
GPR30 expression predict a poor prognosis in ovarian
cancer [35]. This is not yet sufficient evidence of a role
of GPR30 in ovarian cancer. Therefore, it was necessary
to clarify whether GPR30 and the GPR30-dependentactivation of MAPK-ERK1/2 via EGFR transactivation is
important in ovarian cancer. In the current study, we
evaluated the relationship between GPR30 expression
and patient clinicopathological factors by immunohisto-
chemistry in ovarian cancer specimens, and evaluated
whether GPR30 mediates Akt activation via the EGFR,
leading to a poor prognosis for ovarian cancer patients.
Materials and methods
Patients
This study was reviewed and approved by the Institutional
Review Board of the Osaka Medical College and informed
consent was obtained from all patients. The study
included 162 patients with either primary epithelial ovar-
ian cancer (152) or low malignant potential tumors [10]
who underwent a diagnosis and surgical resection in the
Department of Gynecology of Osaka Medical College
Hospital in Japan between 2001 and 2009. In the 162 epi-
thelial ovarian cancer and borderline malignant patients,
an effort was made to perform optimal surgical cytoreduc-
tion and adequate staging, which included at least a total
abdominal hysterectomy with bilateral salpingo-oophorec-
tomy, omentectomy, peritoneal washings and retroperi-
toneal lymphadenectomy. The histology of all tumors was
determined by a gynecological pathologist according to
the WHO criteria (World Health Organization).
Immunohistochemistry
Five-micron sections from tumor tissues, which were
formalin-fixed and embedded in paraffin, were prepared
for the immunohistochemical analyses. The expression
of GPR30 was analyzed as follows: Tumor sections were
incubated at 4°C for 18 h with a GPR30-specific anti-
body, a rabbit polyclonal affinity-purified antibody direc-
ted against the C-terminal of GPR30, at a 1:50 dilution
(LifeSpan BioSciences, Inc.). The EGFR expression was
analyzed using the EGFR Pharm Dx kit (Dako Cytoma-
tion). The expression levels of ERα and ERβ were ana-
lyzed using a Dako Cytomation ER Pharm assay.
The interpretation of the immunohistochemical stain-
ing results was performed by two independent
gynecological oncologists (who were accustomed to
diagnosing gynecological malignancies) who were
blinded to the clinicopathological data. For each core,
the staining intensity (graded considering 0 as negative,
1+ as weak, 2+ as moderate, and 3+ as strong) and the
percentage of cells staining positive (0 – 100%) were
determined. The overexpression of GPR30 and the
EGFR was defined to exist if 50% or more of the tumor
cells exhibited cytoplasmic or membranous staining with
a staining intensity of 2+ or more. The overexpression of
ERα and ERβ was defined to exist if 1% or more of the
tumor cells exhibited nuclear staining with a staining in-
tensity of 1+ or more.
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One human ovarian mucinous adenocarcinoma cancer
cell line, Caov-3, which was obtained from the American
Type Culture Collection (Rockville, MD, USA), was
grown in phenol red free DMEM containing 10% dex-
tran-coated, charcoal-treated fetal calf serum, 100 units/
ml penicillin, and 100 μg/ml streptomycin in a humidi-
fied atmosphere of 5% CO2 with 95% air at 37°C.
Expression plasmids and cDNA transfection
To make the pcDNA3.1-GPR30 expression construct,
the cDNA of the full length GPR30 was amplified by
PCR using a human mammary gland cDNA library as
the template. For the transfection of each sample,
oligomer-Lipofectamine plus complexes were prepared
as follows: 100 pmol of cDNA oligomer were diluted in
250 μl of Opti-MEM (Invitrogen). The Lipofectamine
plus was mixed gently before use, and then a 5 μl aliquot
was diluted in 250 μl of Opti-MEM, mixed gently, and
incubated for 5 min at room temperature. After the 5
min incubation, the diluted oligomer was combined with
the diluted Lipofectamine plus, mixed gently, and incu-
bated for another 20 min at room temperature. The
oligomer-Lipofectamine plus complexes were added to
each well containing cells and medium, and mixed gen-
tly by rocking the plate back and forth. The cells were
incubated at 37°C in a CO2 incubator for 24 h, then the
cells were prepared for each assay.
Proliferation assay
After the seeding, the test cells were incubated with phe-
nol red free DMEM containing 10% dextran-coated,
charcoal-treated fetal calf serum for 24 hours in 96 well
plates. The changes in cell proliferation were examined
by the addition of G1, which is a selective agonist of
GPR30, or G15, which is a selective antagonist, with
serum free DMEM for 48 hours. The number of Caov-3
cells after 48 hours of stimulation was determined by
measuring the dissolved formazan products after the
addition of MTS. All experiments were carried out in
quadruplicate, and the cell viability was expressed as the
ratio of the number of viable cells with G1 stimulation
to that of cells without stimulation.
Western blot analysis
The cells were serum-starved and stimulated with PBS
(phosphate-buffered saline) or 100 nM G1 for 5 min or
15 min. Cells were then washed twice in ice-cold PBS
and lysed, and the cytoplasmic and nuclear fractions
were separated using a Nuclear Extract Kit (Active
Motif, Carlsbad, CA, USA). To detect all of the proteins,
equal amounts of cytoplasmic proteins were separated
by SDS-polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membranes. Blocking was donein 10% bovine serum albumin in 1x Tris-buffered saline.
The Western blot analyses were performed with var-
ious specific antibodies. The immunoreactive bands
in the immunoblots were visualized with horseradish
peroxidase-coupled goat anti-rabbit immunoglobulin
using an enhanced chemiluminescence Western blotting
system (ECL Plus, GE healthcare Life Sciences, Pitts-
burgh, PA, USA). All Western blots were checked for
equal protein loading using Ponceau staining.
Statistical analysis
The statistical analyses in this study were carried out
with the Stat View statistical software package (SAS In-
stitute, Cary, NC, USA). Fisher’s exact probably test was
used to evaluate the correlations between the immuno-
histochemical and clinical data. The endpoints investi-
gated were the progression-free survival and overall
survival. The progression-free survival was defined as
the time from the first day of chemotherapy until disease
progression (based on the findings of imaging studies).
Overall survival was defined as the time from the first
day of chemotherapy to death from any cause. The uni-
variate and multivariate analyses of the histology,
progression-free survival and overall survival were deter-
mined with the Kaplan-Meier method using the log-rank
test and the Cox proportional hazards model, respect-
ively. Differences with p-values < 0.05 were considered
to be statistically significant.
Results
Correlations of GPR30, EGFR, ERα and ERβ with the
clinicopathological features of ovarian carcinomas
The clinical and pathological data for the patients are
shown in Table 1. Of the 162 investigated patients, 10,
39, 14, 77 and 22 were categorized to have a borderline
malignancy, and stage I, II, III and IV ovarian cancer, re-
spectively. Of the 162 cases, 10 were borderline malig-
nant tumors, 61 were histologically diagnosed to be
serous adenocarcinoma, 30 endometrioid adenocarcin-
oma, 19 mucinous adenocarcinoma and 29 were diag-
nosed to be clear cell adenocarcinoma. In the tumor
specimens obtained by surgical resection, the expression
levels of the GPR30, EGFR, ERα and ERβ proteins were
evaluated. A representative example of the immunos-
taining analysis is shown in Figure 1. The expression of
GPR30 and EGFR was detected mainly in the cytoplasm,
and the ERα and ERβ expression was detected mainly in
the nuclei of the tumor specimens.
We also examined the relationships between the clini-
copathological factors and the immunohistochemical
staining patterns, the results of which are shown in
Tables 2 and 3. There were no significant associations
between the GPR30 expression and the patient age or
menstrual status. However, the GPR30 expression
Table 1 Characteristics of borderline malignancy and
epithelial ovarian cancer cases
Variables Number of patients (%)
N=162
Age (years) 54.1 ± 12.5
Postmenopausal 96
Premenopausal 66
BMI 22.0 ± 3.4
Histology Borderline malignancy 10 (6.1%)
Serous adenocarcinoma 61 (37.6%)
Endometrioid adenocarcinoma 30 (18.5%)
Mucinous adenocarcinoma 19 (11.7%)
Clear cell adenocarcinoma 29 (17.9%)
Other 13 (8.0%)
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(p<0.04). The GPR30 expression in ovarian carcinomas was
significantly higher than that in borderline malignancies
(p=0.0016). Interestingly, the GPR30 expression was
significantly related to the histological subtype (p<0.001).
GPR30 expression was observed in 75.4% (46/61) of serousFigure 1 Representative examples of immunohistochemically-stained
sections from tumor specimens that were positive for GPR30 (A), EGFR (B),adenocarcinomas, 83.3% (25/30) of endometrioid adenocar-
cinomas and 73.7% (14/19) of mucinous adenocarcinomas,
while 20.7% (6/29) of clear cell carcinomas were observed
to express the protein.
No significant associations between the EGFR, ERα
and ERβ expression and the patient age, menstrual
status or BMI were observed. The EGFR expression level
in ovarian carcinomas was significantly higher than that
in borderline malignancies (p=0.012), although the ERα
and ERβ expression in ovarian carcinomas was not sig-
nificantly different from that in borderline malignancies.
Interestingly, the ERα expression levels were also signifi-
cantly related to the histological subtype (p=0.004).
Prognostic impact of GPR30, EGFR, ERα and ERβ
expression in ovarian carcinoma
We also examined the relationship between the staining
intensity of various markers and patient survival. The
median survival time for all patients was 5.2 years. Re-
cent studies have shown that GPR30 is expressed in a
variety of estrogen-responsive cancer cells, and that it
activates the epidermal growth factor receptor (EGFR)
transduction pathway in various malignancies [19,20,27-
29]. We therefore examined the GPR30-related status, as
represented by the co-expression of GPR30 and the
EGFR, and its relationship to the patients’ survival. A
high tumor co-expression of GPR30 and EGFR was
significantly associated with a poorer progression-freesections. Representative examples of immunohistochemically-stained
ERα (C) and ERβ (D). Scale bars represent 100 μm.
Table 2 Correlations between GPR30 and EGFR expression and clinicopathological factors
Variables Expression of GPR30 p value Expression of EGFR p value
Positive Negative Positive Negative
Age 54.0 ± 12.7 54.3 ± 12.2 0.49 54.3 ±11.9 53.9 ±13.5 0.84
Premenopausal 40 (60.6%) 26 (39.4%) 0.80 27 (40.9%) 39 (59.1%) 0.39
Postmenopausal 60 (60.6%) 36 (39.4%) 33 (33.3%) 63 (66.7%)
BMI 21.5 ± 2.7 22.6 ± 4.2 0.04 21.4±3.6 22.2±2.8 0.11
Borderline malignancy 1 (10.0%) 9 (90.0%) 0.0016 0 (0%) 10 (100%) 0.012
FIGO stage I 26 (66.7%) 13 (33.3%) 0.31 13 (33.3%) 26 (66.7%) 0.77
II 11 ( 78.6%) 3 (21.4%) 7 (50.0 %) 7 (50.0%)
III 47 (61.3%) 30 (38.7%) 32 (41.6%) 45 (58.4%)
IV 15 (68.2%) 7 (31.8%) 8 (36.4%) 14 (63.6%)
Histology
Borderline malignancy 1 (10.0%) 9 (90.0%) 0.0016 0 (0%) 10 (100%) 0.012
Serous adenocarcinoma 46 (75.4%) 15 (24.6%) <0.001 24 (39.3%) 37 (60.7%) 0.42
Endometrioid adenocarcinoma 25 (83.3%) 5 (16.7%) 11 (36.7%) 19 (63.3%)
Mucinous adenocarcinoma 14 (73.7%) 5 (26.3%) 8 (42.1%) 11 (57.9%)
Clear cell adenocarcinoma 6 (20.7%) 23 (79.3%) 14 (48.3%) 15 (51.7%)
Others 8 (61.5%) 5 (38.5%) 3 (23.1%) 10 (76.9%)
Recurrence 0.30 0.31
≤ 6M 13 (68.4%) 6 (31.6%) 9 (47.4%) 10 (52.6%)
> 6M 43 (67.2%) 21 (32.8%) 20 (31.3%) 44 (68.7%)
No recurrence 44 (55.7%) 35 (44.3%) 31 (39.2%) 48 (60.8%)
5-year survival 0.56 0.86
Alive 63 (61.8%) 39 (38.2%) 35 (34.3%) 67 (65.7%)
Dead 37 (61.7%) 23 (38.3%) 25 (41.7%) 35 (58.3%)
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GPR30 and EGFR expression levels, and the ERα and
ERβ expression levels, were not significantly related to
the survival.
G1 stimulates the proliferation of Caov-3 ovarian
carcinoma cells
In recent studies, GPR30 was reported to regulate the
GPR30-dependent activation of MAPK-ERK1/2 via
EGFR transactivation in breast cancer and endometrial
cancer [17,20]. However, it is unclear whether GPR30-
mediated Akt activation via EGFR transactivation occurs
in ovarian cancer. To assess this possibility, we first eval-
uated the ability of G1, a selective GPR30 agonist, to ac-
tivate a transiently transfected GPR30 gene in an ovarian
cancer cell line (Caov-3 cells). The mRNA expression of
GPR30 in Caov-3 cells was evaluated by semi quantita-
tive RT-PCR (Figure 3A). The mRNA expression of
GPR30 in Caov-3 cells that were not transfected with
the GPR30 gene was significantly lower than that in
Caov-3 cells transfected with the GPR30 gene
(Figure 3A). The proliferation of the Caov-3 cells was
examined using the MTS assay. As shown in Figure 3, aconcentration of 100 nM of G1 enhanced the prolifera-
tion of Caov-3 cells for 48 h in culture ((p=0.0016), and
100 nM of G15, which is a selective GPR30 antagonist,
inhibited the G1-induced proliferation of the Caov-3
cells (Figure 3B) (Western blotting analysis; Additional
file 1: Figure S3).GPR30 signaling initiates EGFR-Akt signaling in ovarian
cancer cells
Next, we ascertained that in Caov-3 cells, rapid phos-
phorylation of the EGFR and Akt were induced by G1
via Src using a Western blot analysis. The mRNA ex-
pression of GPR30 in the Caov-3 cells was confirmed by
semiquantitative RT-PCR (Figure 3A). As shown in
Figure 4A, the phosphorylation of the EGFR could be
significantly enhanced by the addition of 100 nM G1
(p<0.01), to a similar extant as was observed using EGF.
The phosphorylation of Akt could also be significantly
enhanced by 100 nM of G1 (p<0.01) or EGF, and could
be inhibited by PP1, which is a Src family kinase inhibi-
tor (Figure 4B, A2780 cells; Additional file 2: Figure S1,
RMG-1 cells; Additional file 3: Figure S2).
Table 3 Correlations between the clinicopathological factors and estrogen receptors (ERa, ERb)
Variables Expression of ERα p value Expression of ERβ p value
Positive Negative Positive Negative
Age 55.9 ±13.1 52.6±13.1 0.12 55.8 ±12.3 53.6±11.9 0.37
Premenopausal 24 (36.4%) 42 (63.6%) 0.24 16 (24.2%) 50 (75.8%) 0.85
Postmenopausal 41 (42.7%) 55 (57.3%) 20 (20.8%) 76 (79.2%)
BMI 22.3 ±2.5 21.7 ±2.6 0.24 21.7 ± 4.5 22.0 ± 2.9 0.75
Borderline malignancy 5 (50.0%) 5 (50.0%) 0.72 6 (60.0%) 4 (40.0%) 0.08
FIGO stage I 10 (25.6%) 29 (74.4%) 0.99 14 (35.9%) 25 (64.1%) 0.06
II 9 (64.3%) 5 (35.7%) 2 (14.3 %) 12 (85.7%)
III 34 (44.2%) 43 (55.8%) 14 (18.2%) 63 (81.8%)
IV 7 (31.8%) 15 (68.2%) 0 (0%) 22 (100%)
Histology
Borderline malignancy 5 (50.0%) 5 (50.0%) 0.72 6 (60.0%) 4 (40.0%) 0.08
Serous adenocarcinoma 32 (52.5%) 29 (47.5%) 0.004 11 (18.0%) 50 (82.0%) 0.14
Endometrioid adenocarcinoma 16 (53.3%) 14 (46.7%) 4 (13.8%) 26 (86.2%)
Mucinous adenocarcinoma 5 (26.3%) 14 (73.7%) 8 (42.1%) 11 (57.9%)
Clear cell adenocarcinoma 3 (10.3%) 26 (89.7%) 6 (20.7%) 23 (79.3%)
Others 4 (30.8%) 9 (69.2%) 1 (7.7%) 12 (92.3%)
Recurrence 0.14 0.06
≤ 6M 8 (42.1%) 11 (57.9%) 4 (21.1%) 15 (78.9%)
> 6M 31 (48.4%) 33 (51.6%) 10 (15.6%) 54 (84.4%)
No recurrence 26 (32.9%) 53 (67.1%) 22 (27.8%) 57 (72.2%)
5-year survival 0.47 0.06
Alive 41 (40.2%) 61 (59.8%) 26 (25.4%) 76 (74.6%)
Dead 24 (40.0%) 36 (60.0%) 10 (16.7%) 50 (83.3%)
Figure 2 Correlation of the co-expression of GPR30 and EGFR with the progression-free survival or overall survival. (A) A high level of
tumor co-expression of GPR30 and EGFR was significantly associated with a poorer progression-free survival (p<0.001). (B) There was no significant
relationship, but there was a tendency for there to be a correlation between the overall survival and the co-expression of GPR30 and EGFR (P=0.07).
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Figure 3 The proliferation of the Caov-3 cells following stimulation with G1, a selective GPR30 agonist, and G15, a selective GPR30
antagonist. Caov-3 cells were transfected with the pcDNA3.1 vector (Vector alone) or pcDNA3.1-GPR30 (GPR30). (A) The mRNA expression of
GPR30 in Caov-3 cells was confirmed by semiquantitative RT-PCR. (B) The proliferation of the Ca-ov3 cells transfected with pcDNA3.1-GPR30 was
examined using the MTS assay. The Caov-3 cells transfected with pcDNA3.1-GPR30 were treated with G1 (100 nM), G15 (100 nM), or both G1 and
G15 (100 nM each) for 48 hours. The cell number is expressed as a percentage of the control (100%) which Caov-3 cells transfected with
pcDNA3.1-GPR30. The values shown represent the means ±SE of three independent experiments performed in quadruplicate in three different
passages of the cell lines. Significant differences are shown by asterisks: **, p<0.01.
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The current study revealed that the novel estrogen-
responsive receptor, GPR30, is preferentially active in ovar-
ian cancer, similar to breast, endometrial, prostate and lung
carcinomas. Moreover, we also showed that GPR30 was
expressed at higher levels and was more frequently observed
in ovarian cancer than in borderline malignant tumors.
These data are consistent with a previous report [35].
Estrogens stimulate the proliferation of ovarian cancer
cell lines and normal ovarian surface epithelial cells in
culture [36,37]. However, the ER is present in only ~60%Figure 4 G1, a selective agonist of GPR30, induced the phosphorylati
of EGF for 5 min or 100 nM of G1 for 5 min, cells were harvested and used
blotted with anti-phospho EGFR (upper panel) or anti-EGFR (lower panel) a
min, 100 nM of G1 for 5 min, or 10 nM of PP1, followed by G1 treatment. C
phospho Akt (upper panel) or anti-Akt (lower panel) antibodies. The values
separate experiments. Significant differences are indicated by asterisks. **; pof ovarian cancers [13]. We demonstrated that GPR30
overexpression was not associated with the ER expres-
sion. These data suggest the presence of a complicated
relationship between GPR30 and the ER. Although
GPR30 is widely expressed in cancer cell lines and pri-
mary malignant tumors of the breast, endometrium,
prostate and lungs [16,17], the role of GPR30 in ovarian
carcinoma was unclear. Albanito et al. reported that
GPR30 was involved in the proliferation of ovarian can-
cer cells [38]. The signaling pathways employed by
GPR30 activation have not yet been fully elucidated.on of the EGFR and Akt. (A) After treatment with or without 10 nM
to prepare cell lysates. The lysates were subjected to SDS-PAGE and
ntibodies. (B) Cells were treated with or without 10 nM of EGF for 5
ell lysates were subjected to SDS-PAGE and blotted with anti-
shown represent the means ± standard deviation from at least three
<0.01 (Additional file 2: Supplemental data 1).
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of MAPK-ERK1/2 via EGFR transactivation in ER-negative
breast cancer cell lines [20]. This suggests that GPR30 is
the sole receptor responsive to estrogen that leads to
EGFR transactivation in ER-negative breast cancer. The
EGFR is reported to be present in 33-75% [30] of ovarian
cancers, and has been implicated in both the growth and
progression of this disease [31]. In the present study, we
proved that G1, a selective GPR30 agonist, induces the
proliferation of Caov-3 ovarian cancer cells, and that G15,
a selective GPR30 antagonist, inhibits the G1-induced pro-
liferation of Caov-3 cells. Moreover, G1, like EGF, signifi-
cantly enhanced the activation of both the EGFR and Akt
signaling pathways, and the activation of these pathways
was inhibited by PP1, a Src family kinase inhibitor. This
might suggest that GPR30 is involved in a signaling cas-
cade that is transduced via the EGFR, which leads to a
poor prognosis for ovarian cancer, since the phosphoryl-
ation of Akt via the EGFR is key to the development and/
or progression of ovarian cancer [39].
In the present study, we demonstrated that the co-
expression of GPR30 and the EGFR was associated with a
poorer progression-free survival in patients with ovarian
cancer, although we could not confirm the presence of a
correlation between GPR30 and the survival of ovarian
cancer patients, as was the case in a previous report [40].
Our clinical results support the idea that GPR30 regulates
an EGFR cascade, which is closely related to cancer cell
growth and the survival of ovarian cancer patients. We
have previously reported that the phosphorylation of Akt
leads to increased cell survival and is associated with plat-
inum resistance due to its anti-apoptotic effects in ovarian
cancer cells [34], and that it was associated with a poor
overall survival in ovarian carcinoma patients [33]. In the
current study, we also revealed that the cell proliferation
in ovarian cancer were dependent on GPR30.
Of note, we also showed that the expression of GPR30
in clear cell carcinoma was significantly lower than that in
other types of ovarian cancer. Clear cell adenocarcinoma
is well known to have the worst prognosis of the various
subtypes of ovarian cancer because of its resistance to
chemotherapy, which has been attributed to a slow cell
cycle [41]. Clear cell ovarian tumors do not express estro-
gen or progesterone receptors, and endometriosis that
transforms into clear-cell ovarian cancer can become hor-
mone independent during the transformation process
[42]. Pandeet al. reported that GPR30 signaling induces
proliferation and promotes cell cycle progression [23].
Our current results showed that there was low expression
of not only ERα, but also GPR30, in clear cell adenocarcin-
oma, which means that clear cell adenocarcinoma is likely
to have slow proliferation or slow cell cycling. This study
is the first report to show that the expression of GPR30 is
associated with a specific histological subtype. Ourfindings may imply that the poorer prognosis of clear cell
adenocarcinoma (which is related to its resistance to
chemotherapy) correlates with low GPR30 expression, and
might be associated with a slow cell cycle.
Conclusions
We herein demonstrated that the co-expression of GPR30
and EGFR was associated with a poorer progression free
survival in ovarian cancer patients, and that GPR30
activates the phosphorylation of Akt via the EGFR in
ovarian cancer cells. These lines of evidence reinforce
our speculation that GPR30 plays an important role in
ovarian cancer, other than clear cell carcinoma. The
small sample size is a limitation of the present study.
Therefore, further examinations will be needed to fully
elucidate the functions and role(s) of GPR30. However,
these studies can lead to a deeper understanding of
tumorigenesis and may provide improved treatments
for ovarian cancer. We believe that the regulation of
GPR30 may be a potentially useful new therapeutic tar-
get in ovarian cancer.
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